Corbus Pharmaceuticals (CRBP) Corporate presentation summary

Key clinical and financial highlights

• Anticipated 2026 clinical readouts include CRB-701 updates in HNSCC and cervical cancer, CRB-913 dose-finding data in obesity, and CRB-601 dose escalation results.

• $173M in cash and equivalents as of November 2025, with 17.6M shares outstanding (20.5M fully diluted).

Pipeline overview and development status

• Diversified pipeline: CRB-701 (Nectin-4 ADC) in solid tumors, CRB-913 (CB1 inverse agonist) for obesity, and CRB-601 (anti-avβ8 mAb) for solid tumors.

• CRB-701 has FDA Fast Track Designation for HNSCC and cervical cancer.

• CRB-913 is advancing to a 12-week dose-range study in obesity (n=240) in mid-2026.

CRB-701: Next-generation Nectin-4 ADC

• Designed for improved safety, reduced toxicities, and longer half-life compared to PADCEVⓇ.

• Demonstrates better efficacy in low Nectin-4 expressing tumors and lower free MMAE levels than PADCEVⓇ.

• Flexible dosing regimen and ongoing dose optimization studies in HNSCC, cervical, and mUC.